TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04242498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT00656253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 months period of placebo plus 1 month period without placebo
Study: NCT02231242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC
Study: NCT00863642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy within 48 hours of admission
Description: Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
Description: Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
Study: NCT04242498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Study: NCT02467673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized estradiol + progesterone
Description: Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanoparticulate estradiol + progesterone
Description: Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
Study: NCT03200613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 2.5 mg orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
Study: NCT03778970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
Study: NCT04214834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Rapid-wean: 176 treated Slow-wean: 75 treated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Rapid-wean: 176 treated Slow-wean: 75 treated
Study: NCT03778970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Education
Description: A self-management education (2 sessions during 40 minutes) administered by an interactive workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Control Exercises
Description: Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Movement Control Exercises
Description: Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
Study: NCT04302467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid therapy during operation
Description: ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid therapy during operation
Description: ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
Study: NCT02246400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCMP
Description: eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCMP
Description: eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
Study: NCT03083327

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition.
Description: Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic standard care.
Description: Nutrition support will be provided as per usual care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic standard care.
Description: Nutrition support will be provided as per usual care.
Study: NCT03427242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: oral apatinib 750mg qd
Study: NCT00413699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
Study: NCT02409927

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT oil 10g
Description: 10 g of pure MCT oil mixed with skim milk in a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT homogenate 10g
Description: 10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Description: vehicule (skim milk) with a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT oil 20g
Description: 20g of pure MCT oil mixed with skim milk in a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT homogenate 20g
Description: 20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT oil 30g
Description: 30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: MCT homogenate 30g
Description: 30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
Study: NCT01349192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: \<40kg : 15mg/kg daily for 14 days divided every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: \<40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: 1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate oral rinse
Description: for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine solution wipes
Description: whole body wash solution wipes once daily for first 5 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Decontamination
Description: wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks.
Study: NCT03645473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monarch Airway Clearance System
Description: HFCWO Airway Clearance Device
Study: NCT03194828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication reminder
Description: Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication monitoring only
Description: Patients will use an electronic medication monitoring device to record their actual medication use
Study: NCT00460603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 5 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013726
Description: AG-013726 5 mg bid every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: AG-013736 5 mg bid starting dose
Study: NCT00731835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Revascularization
Description: * angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~* stent placement~* atherectomy
Study: NCT04612322

Intervention type: DEVICE
Intervention: Assessment of microvascular function with intracoronary hemodilution
Description: The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
Study: NCT03766763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment).
Study: NCT02766959

Intervention type: OTHER
Intervention: Observational study
Study: NCT01017731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered IV
Study: NCT03896373

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study: NCT03992261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Topical Foam
Description: Foam
Study: NCT04962295

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02500095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 72 hours of fasting
Study: NCT02850159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS and tDCS
Description: Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
Study: NCT02294565

Intervention type: DRUG
Group type: OTHER
Intervention: VST-1001
Description: Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: 99mTc-labeled sulfur colloid
Description: Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
Study: NCT02521012

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 micrograms
Description: Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 100 micrograms
Description: Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
Study: NCT03585894

Intervention type: OTHER
Group type: OTHER
Intervention: Sumatriptan
Description: Receive intravenous infusion of sumatriptan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Receive intravenous infusion of ketorolac
Study: NCT03919669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All Subjects
Description: All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
Study: NCT01092676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Regular Dosing
Description: Regular dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRN dosing Ibuprofen
Description: PRN dosing Ibupofen
Study: NCT00869726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dirucotide
Description: 500mg, intravenous, dosed once every six months for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous, once every six months for 18 months
Study: NCT01797809

Intervention type: DRUG
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
Study: NCT04615338

Intervention type: OTHER
Intervention: no intervension
Description: no intervention needed just observation and description

Intervention type: OTHER
Intervention: no intervension
Description: no intervention needed just observation and description

Intervention type: OTHER
Intervention: no intervension
Description: no intervention needed just observation and description
Study: NCT03237000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.
Study: NCT00592007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant and Erlotinib
Description: Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
Study: NCT02590146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-pharmacologic pain control adjuncts
Study: NCT03906565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
Study: NCT00446134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taribavirin
Description: Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taribavirin
Description: Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taribavirin
Description: Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Study: NCT00663039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose (plus a booster dose) drug probe study using intranasal placebo
Study: NCT02288650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early refeeding

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: refeeding only in the recovery room (usual practice).
Study: NCT02018601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BRILMA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexketoprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Study: NCT02060227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Latarjet procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Bankart repair
Study: NCT03026842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2/day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin, Cytarabine
Description: Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone, Cytarabine
Description: Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclacinomycin, Cytarabine
Description: Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
Study: NCT03728257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTGO-Home Based Exercise
Description: The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
Study: NCT04686500

Intervention type: DEVICE
Group type: OTHER
Intervention: Tidal volume measured by spirometer and DIBH surface from CT image
Description: The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
Study: NCT04513665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25
Description: ZW25 at 20mg/kg intravenously (IV) every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25
Description: ZW25 at 20mg/kg intravenously (IV) every two weeks.